2543 Weekly cabazitaxel in "unfit" metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial. (September 2015) - Fernandez Parra, E.M.; Ochoa, M.; Castellano, D.; Munielo, L.; Juan, M.J.; Perez Valderrama, B.; Mellado, B.; Fernandez Calvo, O.; Anido, U.; Domenech, M.; Hernando, S.; Arranz, J.A.; et al.